Cosmos Health Inc.
COSMHealthcare|Medical - Pharmaceuticals|GR
$0.30
+0.01 (+5.17%)
Tangible Book / Share
$0.20
Cash / Share
$0.03
Financials
Financial Snapshot
Market Cap
$30.7M
Enterprise Value
$44.9M
Revenue (TTM)
$73.7M
Net Income (TTM)
-$24.4M
Cash & Investments
$1.8M
Net Cash
-$14.1M
Free Cash Flow (TTM)
-$11.5M
Operating CF (TTM)
-$11.4M
Debt/Equity
0.77
Cash Runway & Burn Rate
Cash on Hand
$1.8M
Quarterly Burn
$2.8M
Monthly Burn
$946.1K
Est. Runway
~0.6 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $716.6K | $782.9K | $3.6M | $277.5K | $851.2K | $298.0K | $20.8M | $3.9M | $336.3K | $761.8K | $1.8M | |
| Operating Cash Flow | -$2.1M | -$8.8M | -$1.6M | -$4.8M | -$11.5M | -$7.1M | -$14.9M | -$15.6M | -$7.7M | -$8.4M | -$11.4M | |
| Free Cash Flow | -$2.1M | -$8.8M | -$2.1M | -$5.5M | -$11.6M | -$8.0M | -$15.3M | -$24.8M | -$8.1M | -$8.5M | -$11.5M | |
| Capital Expenditure | -$12.8K | -$55.3K | -$503.4K | -$672.8K | -$117.7K | -$890.5K | -$383.1K | -$9.2M | -$418.1K | -$55.7K | -$191.7K | |
| Financing Cash Flow | $2.7M | $9.3M | $2.0M | $3.6M | $12.5M | $7.3M | $35.0M | $12.7M | $5.0M | $14.1M | $15.5M |
R&D Spending
R&D (TTM)
$497.6K
R&D Intensity
0.7%
R&D Growth vs Prior
-4.2%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8M | $30.0M | $37.1M | $39.7M | $55.4M | $56.2M | $50.3M | $53.4M | $54.4M | $65.3M | $73.7M | |
| R&D Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $533.3K | $519.4K | $497.6K | |
| R&D % of Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% | 0.8% | 0.7% | |
| SG&A | $794.1K | $4.9M | $3.6M | $3.5M | $4.9M | $12.4M | $13.2M | $25.6M | $12.1M | $22.5M | $20.5M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8M | $30.0M | $37.1M | $39.7M | $55.4M | $56.2M | $50.3M | $53.4M | $54.4M | $65.3M | $73.7M | |
| Cost of Revenue | $6.2M | $28.1M | $34.7M | $36.0M | $47.3M | $47.9M | $44.4M | $49.0M | $50.1M | $57.4M | $66.2M | |
| Gross Profit | $601.0K | $2.0M | $2.4M | $3.7M | $8.1M | $8.3M | $6.0M | $4.3M | $4.3M | $7.9M | $7.6M | |
| R&D | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $533.3K | $519.4K | $497.6K | |
| SG&A | $794.1K | $4.9M | $3.6M | $3.5M | $4.9M | $12.4M | $13.2M | $25.6M | $12.1M | $22.5M | $20.5M | |
| Operating Income | -$202.5K | -$4.9M | -$1.2M | -$255.8K | $2.7M | -$4.5M | -$7.5M | -$21.8M | -$15.5M | -$16.5M | -$18.2M | |
| Interest Expense | $206.0K | $1.6M | $6.8M | $1.7M | $2.8M | $3.6M | $4.0M | $866.5K | $1.0M | $2.6M | $3.5M | |
| Pretax Income | -$600.2K | -$6.2M | -$9.0M | -$3.1M | $1.2M | -$7.8M | -$13.1M | -$18.5M | -$16.2M | -$19.1M | -$24.4M | |
| Net Income | -$601.0K | -$6.2M | -$9.1M | -$3.3M | $820.8K | -$8.0M | -$13.8M | -$18.5M | -$16.2M | -$19.1M | -$24.4M | |
| EPS (Diluted) | -1.20 | -12.25 | -17.02 | -6.21 | 1.54 | -23.74 | -33.16 | -2.15 | -1.17 | -0.63 | -0.66 | |
| EBITDA | -$384.8K | -$4.5M | -$2.2M | -$988.6K | $4.4M | -$3.8M | -$8.9M | -$17.1M | -$13.9M | -$15.2M | -$19.5M | |
| Shares Out. (M) | 0.50 | 0.51 | 0.53 | 0.53 | 0.53 | 0.66 | 1.93 | 11.97 | 19.15 | 30.29 | 59.92 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $716.6K | $782.9K | $864.3K | $38.5K | $628.4K | $286.5K | $20.7M | $3.8M | $315.1K | $715.7K | $1.8M | |
| Short-Term Investments | $0.00 | $0.00 | $2.7M | $238.9K | $222.8K | $11.5K | $14.9K | $20.1K | $21.1K | $46.2K | $37.5K | |
| Total Current Assets | $2.6M | $9.5M | $18.3M | $21.2M | $40.8M | $39.8M | $56.0M | $36.6M | $25.5M | $38.4M | $36.7M | |
| Total Assets | $3.1M | $10.7M | $20.7M | $23.9M | $43.8M | $49.4M | $68.0M | $66.0M | $54.3M | $65.5M | $61.5M | |
| Total Current Liabilities | $4.9M | $13.7M | $22.3M | $28.2M | $34.3M | $29.9M | $21.7M | $24.3M | $25.8M | $38.3M | $34.8M | |
| Long-Term Debt | $0.00 | $0.00 | $1.6M | $0.00 | $11.3M | $12.7M | $2.9M | $3.0M | $1.6M | $5.9M | $3.0M | |
| Total Liabilities | $4.9M | $13.7M | $24.0M | $30.3M | $48.0M | $45.0M | $28.4M | $30.0M | $29.8M | $47.1M | $40.8M | |
| Stockholders' Equity | -$1.8M | -$3.0M | -$3.3M | -$6.5M | -$4.2M | $4.4M | $39.7M | $36.0M | $24.5M | $18.4M | $20.7M | |
| Retained Earnings | -$1.0M | -$7.2M | -$16.3M | -$19.6M | -$18.8M | -$34.3M | -$66.2M | -$91.6M | -$114.0M | -$133.2M | -$142.1M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.1M | -$8.8M | -$1.6M | -$4.8M | -$11.5M | -$7.1M | -$14.9M | -$15.6M | -$7.7M | -$8.4M | -$11.4M | |
| Capital Expenditure | -$12.8K | -$55.3K | -$503.4K | -$672.8K | -$117.7K | -$890.5K | -$383.1K | -$9.2M | -$418.1K | -$55.7K | -$191.7K | |
| Free Cash Flow | -$2.1M | -$8.8M | -$2.1M | -$5.5M | -$11.6M | -$8.0M | -$15.3M | -$24.8M | -$8.1M | -$8.5M | -$11.5M | |
| Investing Cash Flow | -$144.7K | -$14.5K | -$195.8K | $588.9K | -$117.7K | -$826.8K | -$21.5K | -$13.8M | -$798.3K | -$2.0M | -$2.7M | |
| Financing Cash Flow | $2.7M | $9.3M | $2.0M | $3.6M | $12.5M | $7.3M | $35.0M | $12.7M | $5.0M | $14.1M | $15.5M | |
| Issuance of Stock | $24.1K | $91.8K | $0.00 | $0.00 | $0.00 | $250.0K | $35.3M | $10.0M | $649.0K | $5.4M | $8.4M | |
| Repurchase of Stock | $0.00 | -$34.5K | -$80.1K | -$845.2K | -$200.0K | -$376.9K | $0.00 | -$100.5K | $0.00 | $0.00 | -$513.0K | |
| Net Debt Issuance | $2.7M | $9.2M | $2.1M | $4.4M | $12.7M | $7.4M | -$13.9M | -$21.4K | $548.2K | $10.5M | $7.7M | |
| Stock Based Comp. | $16.6K | $740.6K | $242.0K | $0.00 | $0.00 | $5.9M | $24.4K | $577.9K | $1.7M | $2.3M | $1.7M | |
| Net Change in Cash | $518.5K | $66.3K | $81.5K | -$825.8K | $589.9K | -$341.9K | $20.5M | -$16.9M | -$3.5M | $3.1M | $1.8M |
Dilution Tracker
Shares outstanding grew 5590.1% over 5 years — significant dilution
Shares Outstanding
101M
5-Year Share Growth
+5590.1%
Stock Issuance (TTM)
$8.4M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.50 | 0.51 | 0.53 | 0.53 | 0.53 | 0.66 | 1.93 | 11.97 | 19.15 | 30.29 | 59.92 | |
| Change vs Prior % | — | 1.7% | 4.1% | -0.2% | 0.3% | 23.4% | 193.5% | 520.7% | 60.0% | 58.2% | 97.8% | |
| Stock Issuance | $24.1K | $91.8K | $0.00 | $0.00 | $0.00 | $250.0K | $35.3M | $10.0M | $649.0K | $5.4M | $8.4M | |
| Stock Repurchase | $0.00 | -$34.5K | -$80.1K | -$845.2K | -$200.0K | -$376.9K | $0.00 | -$100.5K | $0.00 | $0.00 | -$513.0K | |
| Stock Based Comp. | $16.6K | $740.6K | $242.0K | $0.00 | $0.00 | $5.9M | $24.4K | $577.9K | $1.7M | $2.3M | $1.7M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 8.9% | 6.5% | 6.5% | 9.2% | 14.5% | 14.8% | 11.8% | 8.1% | 7.9% | 12.1% | 10.3% | |
| Operating Margin % | -3.0% | -16.2% | -3.3% | -0.6% | 4.9% | -8.1% | -14.8% | -40.9% | -28.6% | -25.3% | -24.6% | |
| Net Margin % | -8.9% | -20.7% | -24.4% | -8.3% | 1.5% | -14.2% | -27.5% | -34.7% | -29.7% | -29.3% | -33.1% | |
| EBITDA Margin % | -5.7% | -15.1% | -5.9% | -2.5% | 7.9% | -6.8% | -17.7% | -32.0% | -25.6% | -23.2% | -26.4% | |
| FCF Margin % | -31.7% | -29.4% | -5.6% | -13.8% | -21.0% | -14.2% | -30.3% | -46.5% | -14.9% | -13.0% | -15.7% | |
| ROE % | 34.3% | 205.1% | 273.1% | 51.1% | -19.7% | -181.8% | -34.9% | -51.4% | -66.0% | -103.9% | -118.9% | |
| ROA % | -19.3% | -58.2% | -43.8% | -13.8% | 1.9% | -16.1% | -20.3% | -28.1% | -29.8% | -29.2% | -39.7% | |
| ROIC % | -14.0% | -68.1% | -9.1% | -1.8% | 6.3% | -13.7% | -13.8% | -43.5% | -40.6% | -40.4% | -46.4% | |
| R&D / Revenue % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% | 0.8% | 0.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1165.5% | 344.3% | 23.6% | 7.0% | 39.6% | 1.5% | -10.5% | 6.0% | 2.0% | 19.9% | |
| Gross Profit | 1126.8% | 225.5% | 23.1% | 52.0% | 120.1% | 3.4% | -28.5% | -27.0% | -0.9% | 83.1% | |
| Operating Income | 54.2% | -2306.0% | 74.8% | 79.2% | 1161.1% | -267.0% | -64.9% | -192.1% | 28.8% | -6.4% | |
| Net Income | 91.0% | -933.2% | -45.9% | 63.6% | 124.9% | -1070.0% | -73.7% | -34.1% | 12.7% | -18.3% | |
| EPS (Diluted) | 91.0% | -920.8% | -38.9% | 63.5% | 124.8% | -1641.6% | -39.7% | 93.5% | 45.6% | 46.2% | |
| Operating Cash Flow | -327.7% | -312.0% | 82.2% | -207.9% | -140.2% | 38.3% | -109.5% | -5.1% | 50.6% | -9.5% | |
| Free Cash Flow | -295.3% | -312.2% | 76.6% | -165.3% | -112.7% | 31.3% | -91.0% | -62.6% | 67.2% | -4.5% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -2.6% | |
| SG&A Expense | 63.4% | 511.1% | -26.0% | -1.9% | 40.4% | 150.9% | 6.7% | 93.1% | -52.7% | 86.5% | |
| Total Assets | 374.2% | 242.3% | 93.9% | 15.4% | 83.6% | 12.7% | 37.6% | -3.0% | -17.7% | 20.6% | |
| Book Value / Share | -46.8% | -63.8% | -4.3% | -95.2% | 35.6% | 185.0% | 208.5% | -85.4% | -57.5% | -52.5% | |
| Debt | 574.7% | 218.2% | 62.9% | 16.3% | 66.1% | -15.4% | -55.7% | 3.3% | -4.9% | 68.9% | |
| Diluted Shares | 0.0% | 1.7% | 4.1% | -0.2% | 0.3% | 23.4% | 193.5% | 520.7% | 60.0% | 58.2% |
Valuation
P/E (TTM)At Loss
P/S0.42
10Y Low / Med / High0.17 / 0.98 / 14.59
P/B0.88
10Y Low / Med / High0.22 / 0.52 / 12.64
EV/EBITDAAt Loss
EV/Revenue0.61
10Y Low / Med / High0.00 / 1.46 / 14.96
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$0.20
Cash / Share
$0.03
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -164.00 | -20.82 | -5.88 | -8.86 | 82.26 | -3.55 | -0.14 | -0.66 | -0.57 | -0.79 | -0.46 | |
| P/S Ratio | 14.59 | 4.31 | 1.44 | 0.74 | 1.22 | 0.98 | 0.17 | 0.32 | 0.24 | 0.23 | 0.42 | |
| P/B Ratio | -56.23 | -42.69 | -16.04 | -4.52 | -16.26 | 12.64 | 0.22 | 0.47 | 0.52 | 0.82 | 0.88 | |
| EV/EBITDA | -262.62 | -30.52 | -31.45 | -49.01 | 22.57 | -21.53 | -0.01 | -1.49 | -1.75 | -2.27 | -2.30 | |
| EV/Revenue | 14.96 | 4.62 | 1.86 | 1.22 | 1.79 | 1.46 | 0.00 | 0.48 | 0.45 | 0.53 | 0.61 |
Analyst Estimates & Quality
Altman Z-Score
-2.67
Distress
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $85.4M | $129.6M | $160.8M |
| Net Income | -$4.5M | $2.1M | $4.2M |
| EPS | $-0.15 | $0.07 | $0.14 |
| # Analysts (EPS) | 2 | 2 | 1 |
Revenue Segments
By Product
| Segment | 2023 | 2024 | 2025 |
|---|---|---|---|
| Pharma manufacturing | $344.7K | $865.4K | $1.7M |
| Nutraceuticals and Pharmaceuticals | — | — | $4.3M |
| Wholesale | — | — | $59.3M |
By Geography
| Segment | 2023 | 2024 |
|---|